Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Active, not recruiting
- Conditions
- Prostate CancerBreast CancerLung CancerMelanoma
- Registration Number
- NCT01777802
- Lead Sponsor
- Mayo Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 97
Inclusion Criteria
Inclusion Criteria:<br><br> - Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast<br> Cancer<br><br>Exclusion Criteria:<br><br>-Life expectancy of less than 3 months
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in immune biomarkers from baseline and after radiation treatments for breast, prostate, and lung cancers.
- Secondary Outcome Measures
Name Time Method